COLACI, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.571
EU - Europa 11.633
AS - Asia 6.318
SA - Sud America 914
AF - Africa 161
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 10
Totale 37.624
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.352
IT - Italia 5.154
GB - Regno Unito 2.927
SG - Singapore 2.028
CN - Cina 1.675
SE - Svezia 802
HK - Hong Kong 792
BR - Brasile 705
VN - Vietnam 617
DE - Germania 544
FR - Francia 476
UA - Ucraina 445
FI - Finlandia 426
TR - Turchia 356
RU - Federazione Russa 290
NL - Olanda 152
IN - India 145
BG - Bulgaria 138
KR - Corea 130
ID - Indonesia 114
CA - Canada 93
MX - Messico 84
AR - Argentina 82
JP - Giappone 65
AE - Emirati Arabi Uniti 63
ZA - Sudafrica 56
BD - Bangladesh 53
IQ - Iraq 52
PL - Polonia 38
PK - Pakistan 33
EC - Ecuador 32
ES - Italia 28
BE - Belgio 27
IE - Irlanda 27
MA - Marocco 24
RO - Romania 24
CH - Svizzera 22
MY - Malesia 22
VE - Venezuela 22
CO - Colombia 21
CL - Cile 20
SA - Arabia Saudita 19
IR - Iran 18
TN - Tunisia 18
EG - Egitto 17
AU - Australia 16
LT - Lituania 15
PH - Filippine 15
BZ - Belize 14
UZ - Uzbekistan 14
NP - Nepal 13
AT - Austria 12
KE - Kenya 12
TH - Thailandia 11
AZ - Azerbaigian 10
HU - Ungheria 10
JO - Giordania 10
PY - Paraguay 10
BO - Bolivia 9
CZ - Repubblica Ceca 8
GR - Grecia 8
IL - Israele 8
NO - Norvegia 8
PE - Perù 8
TW - Taiwan 8
BY - Bielorussia 7
EU - Europa 7
KG - Kirghizistan 7
DO - Repubblica Dominicana 6
LB - Libano 6
ET - Etiopia 5
GE - Georgia 5
HN - Honduras 5
HR - Croazia 5
KZ - Kazakistan 5
MD - Moldavia 5
OM - Oman 5
PT - Portogallo 5
RS - Serbia 5
AL - Albania 4
CY - Cipro 4
DZ - Algeria 4
ML - Mali 4
PA - Panama 4
SN - Senegal 4
UY - Uruguay 4
BH - Bahrain 3
CR - Costa Rica 3
DK - Danimarca 3
LU - Lussemburgo 3
PS - Palestinian Territory 3
QA - Qatar 3
SI - Slovenia 3
SK - Slovacchia (Repubblica Slovacca) 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
EE - Estonia 2
GT - Guatemala 2
IM - Isola di Man 2
Totale 37.589
Salva come PNG Salva come JPEG
Città #
Southend 2.236
Fairfield 1.826
Santa Clara 1.581
Ashburn 1.376
Singapore 1.373
Woodbridge 1.068
Houston 841
Hong Kong 780
Chandler 751
Chicago 735
Jacksonville 725
Seattle 685
Wilmington 621
Cambridge 599
Ann Arbor 532
Dearborn 502
San Jose 490
Los Angeles 487
Nyköping 425
Hefei 369
Milan 363
Rome 362
Beijing 346
London 343
Salt Lake City 308
Helsinki 306
Izmir 221
The Dalles 218
Modena 209
Council Bluffs 199
Ho Chi Minh City 181
New York 177
Hanoi 162
Tampa 162
San Diego 148
Princeton 139
Sofia 134
Elk Grove Village 131
Eugene 123
Seoul 123
Dallas 112
Lauterbourg 110
Naples 93
Florence 91
Bologna 90
Jakarta 82
Palermo 82
Sterling 78
Shanghai 77
Frankfurt am Main 75
Bremen 73
Buffalo 73
Redwood City 72
Catania 70
Des Moines 69
Moscow 67
Turin 66
Bari 65
São Paulo 63
Columbus 57
Lancaster 54
Genoa 53
Atlanta 45
Verona 45
Guangzhou 44
Detroit 43
Miami 43
Padova 41
Phoenix 40
Dulles 38
Orem 37
Tokyo 36
Boardman 35
Mexico City 33
Cagliari 32
Norwalk 31
Da Nang 30
Munich 30
Kunming 27
Falls Church 26
Haiphong 26
Denver 25
Toronto 25
Johannesburg 24
Warsaw 24
Amsterdam 23
Chennai 23
Salerno 23
Delhi 22
Dublin 22
Parma 22
Pisa 22
Pittsburgh 22
Baghdad 20
Belo Horizonte 20
Dong Ket 20
Brescia 19
Kansas City 19
Reggio Emilia 19
Brooklyn 18
Totale 25.123
Salva come PNG Salva come JPEG
Nome #
INTERSTIZIOPATIA POLMONARE NON CLASSIFICABILE O SECONDARIA A CONNETTIVITE INDIFFERENZIATA. IMPORTANZA E DIFFICOLTÀ DI UNA DIAGNOSI DIFFERENZIALE. 3.817
ALTERAZIONI CAPILLAROSCOPICHE IN CORSO DI DERMATOMIOSITE E SCLEROSI SISTEMICA; VERSO L’INDIVIDUAZIONE DI PATTERN SPECIFICI 935
Thyroid Involvement in Hepatitis C Virus-Infected Patients with/without Mixed Cryoglobulinemia 758
Semeiotica dell'articolazione temporo-mandibolare 543
Capillaroscopic skin ulcer risk index: a new prognostic tool for digital skin ulcer development in systemic sclerosis patients. 466
Evoluzione dello CSURI (Capillaroscopic Skin Ulcer Risk Index) in pazienti affetti da sclerosi sistemica in terapia con antiendotelina-1 e prostanoidi 444
Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis. 428
Oxycodone in the Long-Term Treatment of Chronic Pain Related to Scleroderma Skin Ulcers. 419
Thymus alterations and systemic sclerosis 383
Systemic sclerosis and cryoglobulinemia: our experience with overlapping syndrome of scleroderma and severe cryoglobulinemic vasculitis and review of the literature. 383
Endocrine manifestations of hepatitis C virus infection. 379
Nailfold Videocapillaroscopy Alterations in Dermatomyositis and Systemic Sclerosis: Toward Identification of a Specific Pattern 369
D-penicillamine in the treatment of eosinophilic fasciitis: case reports and review of the literature. 368
Radiological thymus alterations in systemic sclerosis: our experience and a review of the literature. 368
Heart involvement and systemic sclerosis 355
CXCL10 (α) and CCL2 (β) chemokines in systemic sclerosis - A longitudinal study 348
Systemic sclerosis evolution of disease pathomorphosis and survival. Our experience on Italian patients' population and review of the literature 347
Incidence of thyroid disorders in systemic sclerosis: results from a longitudinal follow-up. 342
Scleroderma digital ulcers complicated by infection with fecal pathogens. 340
Current treatment of hepatitis C-associated rheumatic diseases. 338
Carotidynia Possibly due to Localized Vasculitis in a Patient with Latent Mycobacterium tuberculosis Infection. 337
Aortic pulse wave velocity measurement in systemic sclerosis patients. 336
Breast cancer in systemic sclerosis: Results of a cross-linkage of an Italian Rheumatologic Center and a population-based Cancer Registry and review of the literature 333
IFN-γ and TNF-α induce a different modulation of interleukin-6 in systemic sclerosis fibroblasts compared to healthy controls. 328
Treatment of severe scleroderma skin ulcers with recombinant human erythropoietin 323
High levels of circulating N-terminal pro-brain natriuretic peptide in patients with hepatitis C. 322
Adult-onset Still’s disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients 321
Chemokines in the pathogenesis and as therapeutical markers and targets of HCV chronic infection, and HCV extrahepatic manifestations 321
Elevated Troponin Serum Levels in Adult Onset Still's Disease 319
Cardio-pulmonary disease management in patients with systemic sclerosis: cardio-rheumatology clinic and patient care standardisation proposal 319
Recombinant human erythropoietin stimulates vasculogenesis and wound healing in a patient with systemic sclerosis complicated by severe skin ulcers. 319
Established coronary artery disease in systemic sclerosis compared to type 2 diabetic female patients: a cross-sectional study 318
Serum 25-OH vitamin D levels in systemic sclerosis: analysis of 140 patients and review of the literature 317
L-Arginine in pregnant scleroderma patients 317
Staphylococcus protein A-based extracorporeal immunoadsorption and thalidomide in the treatment of skin manifestation of dermatomyositis: a case report. 315
Efficacia di terapia con immunoassorbimento con proteina A dello stafilococco e talidomide in un caso di dermatomiosite refrattaria. 313
Gynaecological Screening for Cervical and Vulvar Malignancies in a Cohort of Systemic Sclerosis Patients: Our Experience and Review of the Literature 310
High interleukin-6 and tumor necrosis factor-alpha serum levels in hepatitis C infection associated or not with mixed cryoglobulinemia 304
Platelet gel in the treatment of severe scleroderma skin ulcers. 302
Antiendothelial cell antibodies induce apoptosis of bone marrow endothelial progenitors in systemic sclerosis 296
Nailfold capillaroscopic changes in dermatomyositis and polymyositis 295
Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature. 291
Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline 289
Immunopathogenesis of HCV-related endocrine manifestations in chronic hepatitis and mixed cryoglobulinemia 286
Cardiovascular risk and prostanoids in systemic sclerosis 283
Long-term treatment with rituximab in interstitial lung disease related to systemic sclerosis: our clinical experience 280
Haematological Malignancies in Systemic Sclerosis Patients: Case Reports and Review of the World Literature 279
Prevalence and evolution of scleroderma pattern at nailfold videocapillaroscopy in systemic sclerosis patients: Clinical and prognostic implications 278
Interstitial pneumonia with autoimmune features and undifferentiated connective tissue disease: Our interdisciplinary rheumatology-pneumology experience, and review of the literature 277
Associations between Systemic Sclerosis and Thyroid Diseases 276
Induction of CXCL10 secretion by interferon-γ and tumour necrosis factor-α and its inhibition by peroxisome proliferator-activated receptor-γ agonists in cultured scleroderma fibroblasts. 274
CORRELATION OF A QUANTITATIVE VIDEOCAPILLAROSCOPIC SCORE WITH THE DEVELOPMENT OF DIGITAL SKIN ULCERS IN SCLERODERMA PATIENTS 273
Polymyositis following Pandemic Influenza A (H1N1) and 2009-10 Seasonal Trivalent Vaccines 273
Management of cardiopulmonary disease in patients with systemic sclerosis: cardiorheumatology clinic and patient care standardization proposal 272
High circulating chemokines (C-X-C motif) ligand 9, and (C-X-C motif) ligand 11, in hepatitis C-associated cryoglobulinemia. 270
Prediction risk chart for scleroderma digital ulcers: A composite predictive model based on capillaroscopic, demographic and clinico-serological parameters 269
Predictive role of capillaroscopic skin ulcer risk index in systematic sclerosis: a multicentre validation study 266
Endocrine Manifestations of HCV-Positive Cryoglobulinemia 265
CAPILLAROSCOPIC SKIN ULCER RISK INDEX (CSURI) IN SYSTEMIC SCLEROSIS: RESULTS FROM AN ITALIAN MULTICENTER VALIDATION STUDY 262
Correlation of a quantitative videocapillaroscopic score with the development of digital skin ulcers in scleroderma patients 260
New targeted molecular therapies for dedifferentiated thyroid cancer 259
Use of Neem oil and Hypericum perforatum for treatment of calcinosis-related skin ulcers in systemic sclerosis 252
Micro and nanoparticles as possible pathogenetic co-factors in mixed cryoglobulinemia 251
UNCLASSIFIABLE INTERSTITIAL LUNG DISEASE OR UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE? A CHALLENGING DIFFERENTIAL DIAGNOSIS 250
The Expanding Spectrum of Clinical Features in HCV-Related Mixed Cryoglobulinemia 249
HCV-related rheumatic manifestations and therapeutic strategies 249
Treatment of HCV-related mixed cryoglobulinemia 247
Renal Manifestations of Hepatitis C Virus 247
Validation study of predictive value of capillaroscopic skin ulcer risk index (CSURI) in scleroderma patients treated with bosentan 247
The safety of iloprost in systemic sclerosis in a real-life experience 246
IP-10 in autoimmune thyroiditis 245
Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature 245
Advanced oxidation protein products in serum of patients with systemic sclerosis: a possible indicator of clinical evolution 244
[CXCR3 and CXCL10 in autoimmune thyroiditis] 241
Scleroderma Digital Ulcers Complicated by Infection with Fecal Pathogens. 238
Epstein-barr virus reactivation after infliximab in rheumatoid arthritis: a case report. 237
Novel Therapies for Thyroid Autoimmune Diseases 236
RHEUMATOID ARTHRITIS RELATED INTERSTITIAL LUNG DISEASE. RADIOLOGICAL PATTERNS AND CORRELATIONS WITH CLINICAL, SEROLOGICAL AND DEMOGRAPHIC FEATURES OF DISEASE 236
The treatment of skin ulcers in systemic sclerosis: use of granulocyte-colony stimulating factor (G-CSF) in 26 patients 233
Neurologic Complications Associated with Sjögren's Disease: Case Reports and Modern Pathogenic Dilemma 230
Hepatitis C virus syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin's lymphoma, and cancer 229
Osteomyelitis complicating scleroderma digital ulcers. 225
RET TKI: potential role in thyroid cancers. 223
ADULT ONSET STILL'S DISEASE: A MULTICENTER RETROSPECTIVE COHORT STUDY OF 233 ITALIAN PATIENTS 223
CXCL10 in psoriasis 219
Systematic review of 2008-2012 literature and update of recommendations for the use of methotrexate in rheumatic diseases, with a focus on rheumatoid arthritis. 214
Severe alopecia complicating systemic sclerosis 212
PAP-TEST FEATURES IN A COHORT OF SYSTEMIC SCLEROSIS PATIENTS 210
Incidence of thyroid disorders in mixed cryoglobulinemia: Results from a longitudinal follow-up 208
Mixed cryoglobulinemia syndrome: where are we going to? 204
Tocilizumab for the treatment of patients with rheumatoid arthritis and interstitial lung diseases: a case series 203
Trattamento della fascite eosinofila con D-penicillamina: descrizione di 3 casi. 200
Th1 and Th2 chemokine serum levels in systemic sclerosis in the presence or absence of autoimmune thyroiditis. 200
Serum a-Chemokine CXCL10 and b-Chemokine CCL2 Levels in HCV-Positive Cryoglobulinemia 197
PATIENTS WITH MIXED CRYOGLOBULINEMIA AND HCV INFECTION, IN PRESENCE OR ABSENCE OF AUTOIMMUNE THYROIDITIS, HAVE HIGH SERUM LEVELS OF (CXC MOTIF) LIGAND (CXCL)9 AND CXCL11 CHEMOKINES 196
Scleroderma skin ulcers definition, classification and treatment strategies our experience and review of the literature 194
Predictive Value of DLCO Reduction in Scleroderma Patients Without Cardio-Pulmonary Involvement at Baseline 189
High serum levels of silica nanoparticles in systemic sclerosis patients with occupational exposure: Possible pathogenetic role in disease phenotypes 189
Trattamento del dolore in reumatologia con oppioidi: nostra esperienza con ossicodone in pazienti con ulcere cutanee vasculitiche. 188
Increased CXCL9 serum levels in hepatitis C-related mixed cryoglobulinemia, with autoimmune thyroiditis, associated with high levels of CXCL10. 188
Totale 33.011
Salva come PNG Salva come JPEG
Categoria #
all - tutte 141.291
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 141.291
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021953 0 0 0 0 0 0 0 0 0 398 330 225
2021/20222.636 114 259 280 204 100 181 140 135 280 223 390 330
2022/20233.426 395 246 182 231 401 421 209 307 426 133 299 176
2023/20243.048 134 196 196 345 503 260 290 308 88 185 236 307
2024/20256.012 290 120 152 487 1.193 891 405 320 624 321 601 608
2025/202610.036 490 303 670 1.711 2.855 742 1.187 460 874 744 0 0
Totale 37.910